Bolus Versus Continuous Remimazolam for Anesthetic Induction

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset. Because remimazolam does not have analgesic property, it should be used with opioid during general anesthesia. Although the incidence of hypotension is known to be low with remimazolam, hypotension is the one of the most frequent adverse events with remimazolam. Moreover, opioid also can lower blood pressure. Therefore, along with opioid, remimazolam can cause hypotension after anesthetic induction.

This study is aimed to investigate the incidence of hypotension after anesthetic induction with bolus (0.14-0.33 mg/kg) or continuous (6-12 mg/kg/hr) remimazolam administration along with opioid use.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kangbuk Samsung Hospital

Criteria

Inclusion Criteria:

• scheduled for elective surgery under general anesthesia

• adult patient (over 19 years old)

• American Society of Anesthesiology Physical Status I-III

Exclusion Criteria:

• arrythmia

• liver dysfunction

• kidney dysfunction

• uncontrolled hypertension

• uncontrolled diabetes mellitus

• allergic to benzodiazepines

• heart failure

• drug intoxication

• alcohol intoxication